Market Overview:
The global hemorrhagic fever vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of hemorrhagic fever, rising demand for preventive measures against the disease, and technological advancements in the field of vaccine development. Based on type, the global hemorrhagic fever vaccine market is segmented into yellow fever vaccine, dengue vaccine, and Ebola vaccine. The yellow fever vaccines segment dominated the global market in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to factors such as high prevalence of yellow fever virus infection across Africa and Latin America regions and rising initiatives by governments for immunization against this virus. However, with increasing R&D activities for development of new-generation Ebola vaccines that are more efficacious and provide better protection than existing products available in the market; this segment is expected to witness highest growth rate during forecast period 2018-2030. Based on application,the global hemorrhagic Fever Vaccine Marketis divided into investigational useand commercial use segments .
Product Definition:
A hemorrhagic fever vaccine is a type of vaccine that helps protect against hemorrhagic fever, a serious illness caused by viruses. Hemorrhagic fever vaccines are not widely available and are not routinely recommended for most people. However, they may be recommended for certain high-risk groups, such as laboratory workers who work with viruses that can cause hemorrhagic fever.
Yellow Fever Vaccine:
Yellow fever is a viral disease caused by the yellow fever virus (YFV) and classified as a hemorrhagic fever. The disease generally affects the tropical areas of America, Africa, Asia, and Australia. In some countries like Brazil and Mexico, it also occurs in subtropic or temperate regions due to changes in climate.
Dengue Vaccine:
Dengue vaccine is a preparation used to prevent dengue hemorrhagic fever. It is available in two forms, namely, attenuated (previously known as virus serotype 8) and non-attenuated (virus type 2). The vaccine was initially created for use against the dengue virus but has been found effective in preventing both types of hemorrhagic fever caused by these viruses.
Application Insights:
On the basis of application, the global hemorrhagic fever vaccine market is segmented into investigational use and commercial use. The investigational use segment dominated the overall market in terms of revenue share in 2017 owing to high R&D investments by various governments for developing a vaccine against these diseases. In addition, there are a number of ongoing clinical trials for developing vaccines against dengue, yellow fever and Ebola hemorrhagic fever.
The commercialization of these vaccines is expected to witness significant growth over the forecast period due to increasing awareness about preventive healthcare measures among individuals as well as communities across various regions including North America and Europe.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of manufacturers and the high adoption rate for new vaccines are some factors contributing to its growth. In addition, increasing government initiatives coupled with funding from non-profit organizations is anticipated to propel the development of novel hemorrhagic fever vaccines in this region. For instance, on March 17th 2018, New York Blood Center announced funds worth USD X million from Wacoal Corp., Japan that will be used for developing a new vaccine against Ebola virus disease (EVD).
The Asia Pacific is expected to grow at an exponential rate during the forecast period owing to several programs being undertaken by governments as well as non-government organizations aimed at immunizing people against these diseases.
Growth Factors:
- Increasing incidence of hemorrhagic fever across the globe
- Growing awareness about the benefits of vaccination against hemorrhagic fever
- Rising demand for preventive measures against hemorrhagic fever outbreaks
- Technological advancements in vaccine development and production processes
- Growing investments by public and private sector players in research and development of new vaccines
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemorrhagic Fever Vaccine Market Research Report
By Type
Yellow Fever Vaccine, Dengue Vaccine, Ebola Vaccine
By Application
Investigational Use, Commercial Use
By Companies
Sanofi Pasteur, Green Cross, Merk & Co., IAVI
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Hemorrhagic Fever Vaccine Market Report Segments:
The global Hemorrhagic Fever Vaccine market is segmented on the basis of:
Types
Yellow Fever Vaccine, Dengue Vaccine, Ebola Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Investigational Use, Commercial Use
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi Pasteur
- Green Cross
- Merk & Co.
- IAVI
Highlights of The Hemorrhagic Fever Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Yellow Fever Vaccine
- Dengue Vaccine
- Ebola Vaccine
- By Application:
- Investigational Use
- Commercial Use
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemorrhagic Fever Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemorrhagic fever vaccine is a vaccine that helps protect people from contracting hemorrhagic fever, a serious and sometimes deadly illness. Hemorrhagic fever is caused by viruses that attack the blood vessels in the body. The most common type of hemorrhagic fever is dengue, which can be fatal if not treated quickly. Dengue vaccines are available in many countries and help protect people against this virus.
Some of the major players in the hemorrhagic fever vaccine market are Sanofi Pasteur, Green Cross, Merk & Co., IAVI.
The hemorrhagic fever vaccine market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hemorrhagic Fever Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hemorrhagic Fever Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hemorrhagic Fever Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hemorrhagic Fever Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hemorrhagic Fever Vaccine Market Size & Forecast, 2020-2028
4.5.1 Hemorrhagic Fever Vaccine Market Size and Y-o-Y Growth
4.5.2 Hemorrhagic Fever Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Yellow Fever Vaccine
5.2.2 Dengue Vaccine
5.2.3 Ebola Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Investigational Use
6.2.2 Commercial Use
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hemorrhagic Fever Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hemorrhagic Fever Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Yellow Fever Vaccine
9.6.2 Dengue Vaccine
9.6.3 Ebola Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Investigational Use
9.10.2 Commercial Use
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Yellow Fever Vaccine
10.6.2 Dengue Vaccine
10.6.3 Ebola Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Investigational Use
10.10.2 Commercial Use
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Yellow Fever Vaccine
11.6.2 Dengue Vaccine
11.6.3 Ebola Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Investigational Use
11.10.2 Commercial Use
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Yellow Fever Vaccine
12.6.2 Dengue Vaccine
12.6.3 Ebola Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Investigational Use
12.10.2 Commercial Use
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Yellow Fever Vaccine
13.6.2 Dengue Vaccine
13.6.3 Ebola Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Investigational Use
13.10.2 Commercial Use
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hemorrhagic Fever Vaccine Market: Competitive Dashboard
14.2 Global Hemorrhagic Fever Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi Pasteur
14.3.2 Green Cross
14.3.3 Merk & Co.
14.3.4 IAVI
